Role of second hematopoietic stem cell transplantation in relapsed or refractory hematologic malignancies.
Prognosis of patients relapsing after stem cell transplantation (SCT) is poor if no further treatment is given. A second SCT is a limited option in these high-risk patients. We retrospectively analyzed the outcomes of second SCT in acute myeloid leukemia, myelodysplastic syndrome, and acute lymphoblastic leukemia after a first SCT. Twenty-five of 30 patients received second allogeneic SCT. Variables related to survival were disease status before second allogeneic SCT and time interval between transplants more than 1 year (P<.01 and P<.02 in multivariate analysis). Treatment-related mortality was 33% with no impact of the conditioning regimen on overall survival. Second allogeneic SCT in selected patients may be an option in this group with a poor outcome.
Falantes
J F
JF
Hematology, Bone Marrow Transplant Unit, Hospital Universitario Virgen del Rocío, Seville, Spain. josef.falantes.sspa@juntadeandalucia.es
Carrillo
E
E
Márquez
F
F
Carmona
M
M
Espigado
I
I
D015331:Cohort Studies; D019337:Hematologic Neoplasms / Q000601:surgery*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D011379:Prognosis; D012008:Recurrence; D015996:Survival Rate